A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment

Muscle and Nerve

Volumn 46, Issue 6, 2012, Pages 964-970

  Mauermann, Michelle L ^a   Blumenreich, Martin S ^b   Dispenzieri, Angela ^a   Staff, Nathan P ^a  

^a Mayo Clinic College of Medicine   (United States)

^b NONE   (United States)

Author keywords

Bortezomib; Conduction block; Microvasculitis; Multiple myeloma; Polyradiculoneuropathy

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN KAPPA CHAIN; LENALIDOMIDE; METHYLPREDNISOLONE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; DECREASED APPETITE; DEHYDRATION; DISEASE ASSOCIATION; ELECTROMYOGRAPHY; FUNGAL ENDOPHTHALMITIS; HUMAN; LEG EDEMA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NERVE BIOPSY; NERVE BLOCK; NOCARDIOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NERVE MICROVASCULITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; SYSTEMIC VASCULITIS; URINE VOLUME; VOMITING;

EID: 84870155444     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23493     Document Type: Article

References (32)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
2. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095-1110.
3. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008; 13: 275-282.
4. Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007; 69: 573-581.
5. Kelly JJ Jr, Kyle RA, Miles JM, O'Brien PC, Dyck PJ. The spectrum of peripheral neuropathy in myeloma. Neurology 1981; 31: 24-31.
6. Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010; 11: 1086-1095.
7. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005; 18: 673-688.
8. Dispenzieri A, Jacobus S, Vesole DH, Callandar N, Fonseca R, Greipp PR. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 Trial. Leukemia 2010; 24: 1406-1411.
9. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
10. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
11. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
12. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
13. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144: 895-903.
14. Saifee TA, Elliott KJ, Rabin N, Yong KL, D'sa S, Brandner S, et al. Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst 2010; 15: 366-368.
15. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008; 119: 2507-2512.
16. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-3120.
17. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27: 3518-3525.
18. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11: 934-941.
19. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440.
20. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593-1599.
21. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204: 317-325.
22. Ahdab R, Michel M, Neves DO, Andre C, Lefaucheur JP. Persistent multifocal pseudo-conduction blocks in vasculitic neuropathy without antiganglioside antibodies. Muscle Nerve 2009; 40: 290-293.
23. McCluskey L, Feinberg D, Cantor C, Bird S "Pseudo-conduction block" in vasculitic neuropathy. Muscle Nerve 1999; 22: 1361-1366.
24. Sandbrink F, Klion AD, Floeter MK "Pseudo-conduction block" in a patient with vasculitic neuropathy. Electromyogr Clin Neurophysiol 2001; 41: 195-202.
25. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic Inflammatory Polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621-637.
26. Fang B, Song Y, Ma J, Zhao RC. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol 2007; 118: 65-67.
27. Garcia-Navarro X, Puig L, Fernandez-Figueras MT, Dalmau J, Roe E, Alomar A. Bortezomib-associated cutaneous vasculitis. Br J Dermatol 2007; 157: 799-801.
28. Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006; 134: 391-398.
29. Mangiacavalli S, Zappasodi P, Castagnola C, Astori C, Varettoni M, Lazzarino M, et al. Severe intestinal vasculitis in a patient under treatment with bortezomib. Ann Hematol 2007; 86: 923-924.
30. Min CK, Lee S, Kim YJ, Eom KS, Lee JW, Min WS et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 2006; 76: 265-268.
31. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 2005; 18: 598-603.
32. Kurzrock R, Cohen PR. Vasculitis and Cancer. Clin Dermatol 1993; 11: 175-187.